RxDoctor Payments Data

Mariana Marrero Castillo, MD

Internal Medicine · Shreveport, LANPI 1366894859

Payments from drug & device makers

$613in general payments, 2019–2025

Across 19 payments — averaging $32.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$187
  • Amgen$117
  • Novo Nordisk$60
  • Bayer$53
  • Dexcom, Inc.$50
  • Exact Sciences$40
  • plus $105 from 6 others

What the payments were for

  • Food & beverage$613100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$613 in reported general payments places this provider in the 55th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$21,312
Medicare patients
206
Services billed
247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide35$47,500
EliquisApixaban27$23,920
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$4,333
Nifedipine ErNifedipine52$1,685
Albuterol Sulfate HfaAlbuterol Sulfate53$1,623
Atorvastatin Calcium127$1,213
Ventolin HfaAlbuterol Sulfate16$965
Amlodipine Besylate114$684
Carvedilol34$678
Gabapentin38$619
Pantoprazole Sodium61$579
Hydralazine Hcl28$539
ClopidogrelClopidogrel Bisulfate23$434
Fluticasone Propionate18$393
Isosorbide Mononitrate ErIsosorbide Mononitrate19$379

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$60$47,50035 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →